JAMA Dermatology · 2013 · 45 citations · 6 references
MedicineImmunologyPharmacotherapyImmunotherapyInflammationRheumatologyAnti-inflammatory PharmacologyAutoimmune Skin DiseasesInflammatory Disease PharmacotherapyInflammatory Skin DiseasesPsoriatic ArthritisRheumatoid ArthritisAcne PharmacotherapyPsoriasis TherapyPsoriatic DiseasePsoriatic Juvenile Idiopathic ArthritisRefractory Ulcerative ColitisTumor Necrosis Factor Inhibitor TherapyTumor Necrosis Factor Therapy
Tumor necrosis factor (TNF) inhibitors have become important components of the treatment of multiple chronic inflammatory disorders such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn disease, and ulcerative colitis. Furthermore, off-label use of TNF inhibitors has been reported for a variety of other diseases. We report a case of refractory acne conglobata treated with the TNF inhibitor adalimumab.
6